==> picture [508 x 268] intentionally omitted <==

Standard Chem & Pharm Co., Ltd. Stock Symbol : 1720

2024 Investor Conference 11/14/2024

==> picture [320 x 85] intentionally omitted <==

免責聲明 Safe Harbor Notice

==> picture [98 x 91] intentionally omitted <==

本次簡報與討論包含特定預測性的說明，而其內容有關於營運結果、財務狀況，以及對未來事件的預期。因為此等前瞻性說明是有關於未來事件，而且取決於未來發生時的環境因素，所以必然含有風險與不確定性。

本公司將不負擔公開更新或修改這些預測性的說明之義務，無論是出現新資訊、未來發生任何事件，或其他情況。實際結果可能與此等預測性說明推測的內容有重大差異。

In these presentations and discussions, there are certain forward looking statements regarding the results of operation, financial condition and current expectation about future events. As forward-looking statements relate to events and depend on circumstances in the future, they involve risk and uncertainty. We do not undertake any obligation to publicly revise or update any forward looking statements for availability of new information, future events or otherwise. Real result probably differ substantially from those expected in these forward-looking statements.

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

Agenda

 Introduction of Standard Group

 2024 Q1-Q3 Operating Results

Future Operation Strategy

 Corporate Social Responsibility (CSR)

==> picture [98 x 91] intentionally omitted <==

Agenda

 Introduction of Standard Group

 2024 Q1-Q3 Operating Results

 Future Operation Strategy  Corporate Social Responsibility (CSR)

SCP and Related/Affiliated Companies

==> picture [739 x 444] intentionally omitted <==

----- Start of picture text -----

Upstream Manufacture Channels
Syn-Tech (1982; 2005
SCP(1967;
Taiwan Biosim(2017)
Over-The-Counter (OTC))
Western 1995 listed stock)
medicine
Your Chance
Syngen(1999; 2016 OTC) Souriree(1997)
(Invested in 2013;
2024.03 OTC)
Syngen(1999)
Healthcare Multipower
nutrition (Invested in 2012)
Sun-you(1994)
Medical- Syngen (1999)
devices
Ho Yao Biopharm (2021)
Obtained CRO certification In October 2023
© 2024 SCP, Ltd
----- End of picture text -----

==> picture [98 x 539] intentionally omitted <==

----- Start of picture text -----

Q
4
----- End of picture text -----

International Accreditation

==> picture [698 x 47] intentionally omitted <==

----- Start of picture text -----

1998 2000 2008 2009 2010 2017 2024
----- End of picture text -----

==> picture [47 x 50] intentionally omitted <==

==> picture [32 x 42] intentionally omitted <==

The first TW pharmaceutical company to be ISO9001 certified

==> picture [56 x 35] intentionally omitted <==

==> picture [51 x 28] intentionally omitted <==

The first TW company to pass US FDA Subsequent US FDA GMP inspections : no 483 inspection in 2000 Last Inspection : 2022/10/31

==> picture [32 x 42] intentionally omitted <==

SCP received JP PMDA’s FDF Plant and API Plant passed “Certificate of Foreign Drug PMDA GMP Audit in 2018 Manufacturer” in 2008

==> picture [56 x 34] intentionally omitted <==

==> picture [64 x 41] intentionally omitted <==

2009

==> picture [54 x 38] intentionally omitted <==

SCP’s API plant passed AU TGA inspection

==> picture [49 x 39] intentionally omitted <==

==> picture [54 x 40] intentionally omitted <==

2010 SCP passed TW PIC/S GMP inspection 2012 SCP is certified GDP by the T-FDA 2012 SCP passed K-FDA inspection

==> picture [54 x 37] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

Agenda

 Introduction of Standard Group

 2024 Q1-Q3 Operating Results

 Future Operation Strategy  Corporate Social Responsibility (CSR)

Consolidated Income Statement

Items	2024 Q1-Q3	2023 Q1-Q3	Diff.	Annual changes (%)
(Unless otherwise specified, expressed in thousands of New Taiwan Dollars)
Operating revenue	5,116,081	4,647,560	468,521	10.1%
Gross profit	2,249,073	2,035,285	213,788	10.5%
Gross profit margin	43.96%	43.79%	0.17%
Operating expenses	1,188,288	1,082,817	105,471	9.7%
Operating profit	1,060,785	952,468	108,317	11.4%
Non-operating income and expenses	206,577	223,387	(16,810)	-7.5%
Profit before income tax	1,267,362	1,175,855	91,507	7.8%
Profit for the year	1,004,028	947,469	56,559	6.0%
Profit attributable to Shareholders of the parent	685,865	673,176	12,689	1.9%
EPS(NTD)	3.84	3.77	0.07	1.9%
2024 SCP, Ltd

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Comparison of Quarterly Revenue of Past 5 Years (Consolidated)

Expressed in thousands of NTD

0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2020 2021 2022 2023 2024 20 21 21 23 24 22 20 21 23 24 22 20 21 23 24 22 20 21 23 22	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2020 2021 2022 2023 2024 20 21 21 23 24 22 20 21 23 24 22 20 21 23 24 22 20 21 23 22	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2020 2021 2022 2023 2024 20 21 21 23 24 22 20 21 23 24 22 20 21 23 24 22 20 21 23 22	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2020 2021 2022 2023 2024 20 21 21 23 24 22 20 21 23 24 22 20 21 23 24 22 20 21 23 22	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2020 2021 2022 2023 2024 20 21 21 23 24 22 20 21 23 24 22 20 21 23 24 22 20 21 23 22	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2020 2021 2022 2023 2024 20 21 21 23 24 22 20 21 23 24 22 20 21 23 24 22 20 21 23 22	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2020 2021 2022 2023 2024 20 21 21 23 24 22 20 21 23 24 22 20 21 23 24 22 20 21 23 22
	Q1	Q2	Q3	Q4	Total	Growth(%)
2020	1,034,417	1,108,059	1,045,351	1,117,573	4,305,400	+9.4%
2021	1,101,113	1,149,060	1,120,840	1,233,069	4,604,082	+6.9%
2022	1,237,170	1,481,061	1,549,872	1,583,265	5,851,368	+27.1%
2023	1,493,025	1,509,004	1,645,531	1,592,208	6,239,768	+6.6%
2024	1,613,535	1,760,104	1,742,442		5,116,081	+10.1%

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Consolidated Balance Sheet

Items	2024/09/30	2024/09/30	2023/09/30	2023/09/30	Diff.	Annual changes(%)
(Expressed in thousands of NTD)	Amount	%	Amount	%
Cash and cash equivalents	1,465,665	13.1%	1,956,260	17.9%	(490,595)	-25.1%
Accounts receivable	1,384,362	12.4%	1,445,772	13.2%	(61,410)	-4.2%
Inventories	1,628,251	14.6%	1,520,828	13.9%	107,423	7.1%
Investments	1,694,628	15.2%	1,099,750	10.0%	594,878	54.1%
Property,plant and equipment	4,025,128	36.1%	4,004,833	36.6%	20,295	0.5%
Others	964,910	8.6%	926,081	8.5%	38,829	4.2%
Total Assets	11,162,944	100.0%	10,953,524	100.0%	209,420	1.9%
Current Liabilities	1,685,380	15.1%	2,535,532	23.1%	(850,152)	-33.5%
Non-current Liabilities	597,177	5.3%	591,278	5.4%	5,899	1.0%
Total liabilities	2,282,557	20.4%	3,126,810	28.5%	(844,253)	-27.0%
Total shareholder’s equity	8,880,387	79.6%	7,826,714	71.5%	1,053,673	13.5%
Debt Ratio(Liabilities/Assets)		20.4%		28.5%
2024 SCP, Ltd

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Consolidated Cash Flows

Items	2024 Q1-Q3	2023 Q1-Q3
(Expressed in thousands of NTD)
Cash at beginning ofyear	2,036,743	2,259,381
Cash flows from operatingactivities	1,154,134	910,300
Acquisition ofproperty, plant and equipment	(360,646)	(488,791)
Cash dividends	(482,479)	(446,740)
Short & long-term borrowings	(549,308)	(230,713)
Investment and others	(332,779)	(47,177)
Cash at end ofyear	1,465,665	1,956,260

Free cash flow (Cash flows from operating activities-Acquisition of property, plant and equipment)	793,488	421,509

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

1720 SCP net profit after tax and EPS in 2024 Q1-Q3

0.30 0.30 0.70 1.20 1.50 1.25 1.20 1.60 0.50 1.00 1.20 2.50 1.00 1.50 1.50 1.60 1.50 1.50 1.80 2.50 2.50 2.70 2.092.15 1.771.81 1.88 1.351.47 1.61 1.73 2.091.951.902.03 2.09 2.11 2.93 3.95 4.56 . 3.84

NTD Thousand

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Q 11

1777 SYN-TECH’s net profit after tax and EPS - in 2024 Q1 Q3

NTD Thousand

==> picture [773 x 328] intentionally omitted <==

----- Start of picture text -----

NTD Thousand NTD
350,000 9
8
300,000
6.77
6.62
7
6.21
250,000 5.63
5.03 6
5.12 [5.31 ]
4.93 [5.20 ] [5.27 ]
200,000 5
150,000 3.33 3.38 4
3.10
2.93
2.37 3
2.15
100,000 1.74 2.19 1.89 3.00
1.00 3.50 3.50 1.99 3.30 [3.50] [4.00] [3.50] 2
50,000 2.00 [2.40] 1.30 1.93 [3.00]
1.75 1
1.70 1.52 [1.00] [2.30] 0.50 2.00
0 0
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

8279 Syngen’s net profit after tax and EPS in 2024 Q1-Q3

NTD Thousand

NTD

==> picture [777 x 404] intentionally omitted <==

----- Start of picture text -----

NTD
400,000 14.00
11.85
350,000
12.00
10.14
300,000
10.00
8.77
250,000 7.86 7.95
8.00
6.71
6.43
200,000
5.8
6.00
4.69
150,000
3.76
5.00 5.00 4.00
100,000
3.50
2.04 4.00
2.00
50,000 1.00 1.00
2.50
3.00
0.50
0.00 1.00
0 0.00
© 2024 SCP, Ltd
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

Agenda

 Introduction of Standard Group

 2024 Q1-Q3 Operating Results

 Future Operation Strategy

 Corporate Social Responsibility (CSR)

Future Milestone

==> picture [794 x 100] intentionally omitted <==

==> picture [130 x 165] intentionally omitted <==

From Taiwan to International From Generics to Better than Generics (BTG)

==> picture [300 x 77] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Significant Business Activities in Recent Years

Japan

==> picture [32 x 28] intentionally omitted <==

Taiwan • Clinic and hospital continued growth.
China • New import license obtained: 1 cases

• Continues to be sold: 2 cases (bronchiolitis and oral antiinflammatory and pain relief medications.)

• Accumulated technology transfer licenses: 3 cases

Establishment of a subsidiary in Vietnam.
Establishment of a GSP distribution center in Vietnam.

• Contracts in progress: 2 cases Agency: 2 cases Gout new medicines certification in 2025. Nasal spray generic medicines, with a submission certification in 2026.

Consistency
Evaluation(GQCE) reviews in progress:

• Establishment of marketing team for Philippines subsidiary

3 cases. (including 1 newly submitted in September 2024)

==> picture [37 x 37] intentionally omitted <==

Projects initiated/Under R&D: 2 cases.

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Revenue Growth Strate -Taiwan gy

==> picture [145 x 205] intentionally omitted <==

EPS Company 2024 Q1~Q3 SCP (1720) 3.84 Syn-Tech (1777) 6.77 Syngen (8279) 6.71 We Can (6929) (0.31)

Specializing in four key areas, with an excellent management team and capabilities.

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

 SCP: Western medicines

Syn-Tech: APIs
Syngen: Health supplements
We Can: Pharmaceutical chain stores

Q

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

17
----- End of picture text -----

China Market Trends: Current

Negotiations and bidding are underway for 162 drugs, marking a three-year high. The results are expected to be announced in November, with implementation starting on January 1, 2025.
• The 10th round of national procurement has commenced, with the total number of drugs collected at both national and provincial levels expected to reach at least 500.

Key Pharmaceutical Focus in 2024

The national healthcare insurance platform will provide a unified portal, allowing price verification in one province to be applied
Drug nationwide, reducing administrative burdens for both companies
PricesNational and the government.
•
Standardization
Trial operation will begin before December 31, with official .
implementation on January 1, 2025

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Q

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

18
----- End of picture text -----

Revenue Growth Strate - China gy

Strategy

==> picture [81 x 81] intentionally omitted <==

==> picture [77 x 61] intentionally omitted <==

Achievements in getting licenses

Own brand and tech transfer simultaneously
3 cases for tech transfer
- 1 case for import license
CDMO
Expand the number of collaborative projects and pharmaceutical companies

NMPA Consistency Evaluation

 3 cases submitted for evaluation

Medium-term targets

Self-developed products submission
Tech transfer profit sharing revenue

Project initiation/Research in progress

Cooperation

Tech-transfer
2 cases in progress
Joint ownership of License

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Cooperative production and marketing
Profit-sharing Partnerships

Japan Market Trend- Ministry of Health, Labour and Welfare 2024 Dru Pricin S stem Reform g g y

Target for Generic Drug Usage Rate and Total Amount

By the end of 2029, the usage rate of generic drugs in all prefectures must reach 80% or more.
• By the end of 2029, the proportion of total spending on generic drugs must be 65% or more
Measures for Patient Co-Payment on Newly Launched Drugs in October
• When patients request brand-name drugs, they will be charged a quarter of the price difference with generic drugs.
• High-priced drugs, central nervous system medications, and pediatric drugs are experiencing significant impacts.
Measures are in place to address increases in production costs for pharmaceutical companies where prices have risen by 8% or more.
Restriction on the Price of Generic Drugs from Multiple Suppliers
• When there are more than 7 suppliers , the price of generic drugs will be set at 40% of the brandname drug price.

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Q

Strengthening Support for Unprofitable Drugs

Due to rising raw material costs, certain drugs are subject to price readjustments targeted at specific companies.

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

20
----- End of picture text -----

Revenue Growth Strategy - Japan

==> picture [81 x 71] intentionally omitted <==

==> picture [76 x 72] intentionally omitted <==

Strategy

Collaboration Model

Agent for brand new drugs.
CDMO
Collaborating with Japan pharmaceutical company to enter other markets.
Japan marketing partner
Strategic alliance with API manufacturer.
Self-owned license
API Vertical Integration with Syn-Tech.

==> picture [78 x 74] intentionally omitted <==

----- Start of picture text -----

•
----- End of picture text -----

Current State

On Going

2 items continue sales
CDMO/CMO
2 new signed CDMO collaboration
- Common items for China/ Southeast Asia/ Japan are under discussion
Acting as an agent for a new gout
medication and nasal spray

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

generic drug, registration is in

progress.

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

21
----- End of picture text -----

The price of generic versions of blockbuster drugs in the U.S. is less than 10% of the ori inal brand rice. g p

==> picture [771 x 371] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

The U.S. market is actively promoting generic drugs to reduce the healthcare burden.

==> picture [512 x 408] intentionally omitted <==

==> picture [108 x 55] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

23
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

Revenue Growth Strate – U.S.A. gy

==> picture [174 x 125] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

U.S.A. Market

Application process for drug licenses is costly, time-consuming, and requires longterm planning

==> picture [65 x 65] intentionally omitted <==

Target products with patents expiring in 5 years or more.
Increase the number of sales items and cooperating manufacturers.

==> picture [65 x 65] intentionally omitted <==

Strategy

Co-develop new products with pharmaceutical companies and dealers.

Current Status

Two drugs have been shipped: (spinal muscular atrophy, and lipid-lowering.)
• The lipid-lowering drug launched in 2023 has Q achieved a 13% market share.
Strategic alliances with raw material suppliers
API Vertical Integration with Syn-Tech.
Actively participated in exhibitions to expand business.
Seeking Early Market Entry for First to File.

Future Operation Strategy

2024 、 Southeast Asia 、 China Japan

Future From Taiwan to International From Generics to BTG

2025 、 USA Japan

Core techniques and professional Oversea marketing 核心技術 skills to expend & 專業海外市場操作 practices oversea sales 借力使力

Increasing oversea Resource proportion 增加海

外比例
Increase resources for overseas business.
Establish a solid foundation.
Use mature Taiwanese technology to create R&D wealth.
Quickly generate revenue.
Recruit and train international talents.
Learn the rules of the game. in various markets.
Jointly plan and operate markets with foreign companies.
Seek for long-term partners.

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Q

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

25
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

Agenda

 Introduction of Standard Group

 2024 Q1-Q3 Operating Results

 Future Operation Strategy  Corporate Social Responsibility (CSR)

Net Zero Emissions and Sustainable Develo ment p

Energy Management

Waste Management

• Engage qualified environmental service providers and recycling businesses certified by the Environmental Protection Agency to carry out cleaning and treatment or resource reuse. • Submit a waste cleanup plan in accordance with the law, implement it after review and approval. Select waste transporters and treatment facilities with legal registration and Class A licenses.

Replacing T5 fluorescent lights with LED lights, resulting in an annual electricity savings of approximately 70,062 kWh.
Changing the nighttime fan operation of the air conditioning unit from 50Hz to a reduced frequency of 35Hz saves 476,538 kWh annually.
Implementing maintenance, recycling hot water, adjusting system parameters, optimizing water production conditions, etc., effectively reduce carbon emissions, improve costeffectiveness, and save energy.

• Conducting periodic maintenance of pipelines to reduce unnecessary water loss due to leaks. • Regularly disclosing Company's water usage to remind employees to conserve water resources.

Water Resource Management

Prioritizing the use of water-saving equipment to reduce water wastage.

Optimizing the production process and product design to reduce unnecessary water usage while improving production efficiency.

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

2024 Net-Zero Industry Competitiveness – 1st Place / 3rd Place(21st Century Foundation)

==> picture [273 x 222] intentionally omitted <==

==> picture [347 x 405] intentionally omitted <==

==> picture [265 x 217] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

Occu ational Safet Model / Excellent Unit p y

==> picture [221 x 255] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

Social Care and EngagementFan Dao Nan Foundation

==> picture [184 x 137] intentionally omitted <==

Introduction to the foundation

Established in 1987
Endowment Fund: NT$196 Million
Annual Budget: NT$12 Million

==> picture [186 x 136] intentionally omitted <==

Principal Activities

Cultural and educational development activities
Public education affairs
Children’s education and happiness
Scholarships and Talent Cultivation

==> picture [186 x 138] intentionally omitted <==

Rewards and Honors Received

2011: Special Recognition Award – Ministry of Education
2012: Tainan City Govt. Grant for Scholarship Program
2013: National Special Selection Award for After-School Program – Dept. of Education
2022: Group Award on Social Education Contribution by Ministry Of Education

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

Q

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

30
----- End of picture text -----

Social Care and Engagement-2024 Corporate Social Responsibility

==> picture [914 x 405] intentionally omitted <==

----- Start of picture text -----

Scholarships
Hope After-school Class Sunflower Wednesdays
 Pharmaceutical or related major: 2
universities/ 4 students
High school :6 schools, totaled 150 •Weekday afternoons •Every Wednesday afternoons
students
Middle school:51 schools, totaled •19 schools，1,045 students •4 Schools，220 students
687 students
 Elementary school: 221 schools,
totaled 2,524 students
NTD 0.90 million NTD 0.40 million
NTD 6.37 million
Other Sponsorships Meal-Assistance Charity
  
Sponsor 12 public welfare Provided 6,950 meals SCP Children’s Drawing
Competition NTD1 million
organizations.
 Q
(Chi Po-lin Foundation) SCP National Table Tennis
Competition NTD1.91 million
NTD 0.62 million NTD 0.70 million NTD 2.91 million
31
----- End of picture text -----

Social Care and Engagement-The 39[th] SCP Children's Drawing Competition

Held on October 19, 2024, at Wanpi World Safari Zoo, with 773 participating students and 779 accompanying teachers and parents, totaling 1,552 people.

==> picture [178 x 246] intentionally omitted <==

==> picture [249 x 180] intentionally omitted <==

==> picture [247 x 180] intentionally omitted <==

Middle Grade Category - Gold Award

Upper Grade Category - Gold Award

==> picture [249 x 175] intentionally omitted <==

==> picture [257 x 171] intentionally omitted <==

Lower Grade Category - Gold Award

Kindergarten Category - Gold Award

SCP Volunteers

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [49 x 49] intentionally omitted <==

----- Start of picture text -----

32
----- End of picture text -----

- - Social Care and Engagement Senior Gym Athletic Training and Health Center

==> picture [164 x 206] intentionally omitted <==

==> picture [310 x 206] intentionally omitted <==

==> picture [296 x 204] intentionally omitted <==

==> picture [276 x 195] intentionally omitted <==

Jan. to Oct. 2024,

Accumulated a total of 109,723 user times.
Held 24 health and wellness seminars and fitness courses, providing knowledge on nutritional care, muscle strengthening exercises, and senior fitness courses.

==> picture [98 x 91] intentionally omitted <==

==> picture [65 x 65] intentionally omitted <==

==> picture [68 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

Q & A

==> picture [64 x 64] intentionally omitted <==

AI assistant

S.C.P.C — Interim / Quarterly Report 2024

51900_rns_2024-11-13_1606524f-0fcf-4062-9486-d6980d4703a5.pdf

Standard Chem & Pharm Co., Ltd. Stock Symbol : 1720

免責聲明 Safe Harbor Notice

Agenda

Agenda

SCP and Related/Affiliated Companies

International Accreditation

Agenda

Consolidated Income Statement

Comparison of Quarterly Revenue of Past 5 Years (Consolidated)

Expressed in thousands of NTD

Consolidated Balance Sheet

Consolidated Cash Flows

1720 SCP net profit after tax and EPS in 2024 Q1-Q3

NTD Thousand

1777 SYN-TECH’s net profit after tax and EPS - in 2024 Q1 Q3

NTD Thousand

8279 Syngen’s net profit after tax and EPS in 2024 Q1-Q3

NTD Thousand

NTD

Agenda

Future Milestone

From Taiwan to International From Generics to Better than Generics (BTG)

Significant Business Activities in Recent Years

Revenue Growth Strate -Taiwan gy

Q

China Market Trends: Current

Q

Revenue Growth Strate - China gy

Strategy

Achievements in getting licenses

NMPA Consistency Evaluation

Medium-term targets

Project initiation/Research in progress

Cooperation

Japan Market Trend- Ministry of Health, Labour and Welfare 2024 Dru Pricin S stem Reform g g y

Target for Generic Drug Usage Rate and Total Amount

Q

Strengthening Support for Unprofitable Drugs

Revenue Growth Strategy - Japan

Strategy

Collaboration Model

Current State

On Going

The U.S. market is actively promoting generic drugs to reduce the healthcare burden.

Revenue Growth Strate – U.S.A. gy

U.S.A. Market

Strategy

Current Status

Future Operation Strategy

Q

Agenda

Net Zero Emissions and Sustainable Develo ment p

Energy Management

Waste Management

Water Resource Management

2024 Net-Zero Industry Competitiveness – 1st Place / 3rd Place(21st Century Foundation)

Occu ational Safet Model / Excellent Unit p y

Social Care and EngagementFan Dao Nan Foundation

Introduction to the foundation

Principal Activities

Rewards and Honors Received

Q

Social Care and Engagement-2024 Corporate Social Responsibility

Social Care and Engagement-The 39[th] SCP Children's Drawing Competition

- - Social Care and Engagement Senior Gym Athletic Training and Health Center

Q & A

More from S.C.P.C

S.C.P.C Interim / Quarterly Report 2024